Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. - Wikidata - wikimedia - TriplyDB

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

http://www.wikidata.org/entity/Q33902419

about

A review of anti-VEGF agents for proliferative diabetic retinopathy Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads.Emerging roles for antiangiogenesis factors in management of ocular disease.Systematic review and meta-analysis of 16 randomized clinical trials of radix astragali and its prescriptions for diabetic retinopathy.Protective measures against ultrafiltration failure in peritoneal dialysis patients Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy Complications of intravitreal injections in patients with diabetes.Mild endoplasmic reticulum stress promotes retinal neovascularization via induction of BiP/GRP78.Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.Intravitreal administration of bevacizumab: pros and cons.Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.Imbalance of the Nerve Growth Factor and Its Precursor: Implication in Diabetic Retinopathy.Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema.

P2860

Q27025643-FCD46263-29AE-4292-868F-103005AA6474 Q34553087-147B26D5-1298-4610-8E04-A456D0499F78 Q36696513-8F54B2CE-7452-466A-9E69-71754C1462BD Q36746311-28DA60BD-A18A-4083-8B2D-46F5510ABF44 Q37970606-1B086044-A453-4643-8802-AF2CEC9758D3 Q38110731-804E8F67-2D2B-4ECD-A58C-708950962CAC Q38193826-2FD23C13-5E17-4A97-B033-CF4590FC5231 Q38261106-069FBB51-569F-4B84-A612-9ECEFBDC67D0 Q39356067-6E470CE4-CBB5-4EAD-84A6-00C079E856D2 Q39357577-92F82E78-7403-4B69-A0EF-EECE9CE8F10F Q39865676-87E9DEA2-6459-4B5A-9096-2035539B0AFF Q41091625-3183E17E-49AD-4001-9C9A-79E803433DA1 Q41839716-EF8040DB-C860-4E5F-B311-67080FD2D91A Q51701226-6AFF5823-62AE-4EB0-A08D-1A4CDFE4769A

P2860

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

http://www.wikidata.org/entity/Q33902419

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

@ast

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

@en

type

label

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

@ast

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

@en

prefLabel

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

@ast

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

@en

P1433

Q33902419-A51C6C45-85B8-44F2-9C00-B6A683BFB8B1

P1476

Q33902419-741A5EDC-1F95-41F6-AAF1-CED4ED6CD52C

P2093

Q33902419-07C32368-2C22-498F-B4D1-281044548CF3

Q33902419-1781FB02-278B-4211-92D3-6823D4315022

Q33902419-4767A0EC-F06B-478F-9C75-F22A5A46AFEB

Q33902419-6131877C-4E0B-4477-A4E2-549726BD049B

Q33902419-6BFF8438-F1C8-4C22-9F59-9FDA6A8FE68B

Q33902419-73E9B6E4-2B7F-4250-B86C-F1508E7E2D37

Q33902419-7BCB1455-86F1-46D4-B17F-895029B08795

Q33902419-80F2B7AA-0167-4442-BD58-821AE537288E

Q33902419-85A6CE46-760D-4527-A9E0-459E4C96A99E

Q33902419-9D5CD899-DA83-47DE-B4A0-103293F337E4

P2860

Q33902419-047134A0-7227-4C7D-A010-77D11D2B924F

Q33902419-08C4EA53-B627-433C-A215-D3C71457C656

Q33902419-0A41AE79-7999-454A-9F1C-CA4832420F67

Q33902419-0D8FB418-1D23-4858-92E8-D5ABBE7999BF

Q33902419-151F47D5-CA98-4531-9FCA-B9972135EE61

Q33902419-22AA9508-AE21-4079-9F3C-33A59128EF01

Q33902419-2F5BF076-24A8-47AE-AB37-0D6DEA51EFC6

Q33902419-2FE971ED-E008-42FA-9DB2-C83A3741EDB5

Q33902419-3377DA1C-4AD6-49C8-BEC5-7352D4C79CE3

Q33902419-37A07493-04AA-435D-AFB2-9909F8C38FA3

P304

Q33902419-BE6186F7-1F7D-47D6-ACBE-50AB2301877E

P31

Q33902419-817C936F-41FD-417F-9CD7-721AEEBDBD02

P356

Q33902419-353F6BD1-D55A-4DB4-9146-CD94112720CF

P478

Q33902419-B003901A-48F3-4D35-BFAC-9AD2B9409F36

P50

Q33902419-5BFF29A1-12AE-4CC9-BE27-8239B6AB0A5A

Q33902419-ECD3AA45-421B-4B8D-9424-E35C6F6448F8

P577

Q33902419-9B76863F-A478-4E5E-B31C-FC5C65B87029

P5875

Q33902419-40FF7EBE-BBB9-466F-AD60-5330644609E0

P698

Q33902419-FFC4CBA4-837C-4ADB-B552-BD9C2F64EC1A

P921

Q33902419-039E91AC-9A5C-4710-AD56-AA1854C55911

P932

Q33902419-D982277D-A2A9-4A18-9301-B8078D9FF4B8

P356

P1433

Journal of Ophthalmology

P1476

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

@en

P2093

Andres F Lasave

http://www.w3.org/2001/XMLSchema#string

Arturo A Alezzandrini

http://www.w3.org/2001/XMLSchema#string

J Fernando Arevalo

http://www.w3.org/2001/XMLSchema#string

Juan G Sanchez

http://www.w3.org/2001/XMLSchema#string

Lihteh Wu

http://www.w3.org/2001/XMLSchema#string

Maria H Berrocal

http://www.w3.org/2001/XMLSchema#string

Mario Saravia

http://www.w3.org/2001/XMLSchema#string

Michel Eid Farah

http://www.w3.org/2001/XMLSchema#string

Miguel Brito

http://www.w3.org/2001/XMLSchema#string

Natalia Restrepo

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Vascular endothelial growth factor is a secreted angiogenic mitogen

Global and societal implications of the diabetes epidemic

Vascular-specific growth factors and blood vessel formation

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group.

Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer.

Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina.

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy.

P304

584238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/584238

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P50

Jans Fromow-guerra

P577

2011-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51138575

http://www.w3.org/2001/XMLSchema#string

P698

21584260

http://www.w3.org/2001/XMLSchema#string

P921

P932

3090772

http://www.w3.org/2001/XMLSchema#string